Journal of International Oncology ›› 2021, Vol. 48 ›› Issue (5): 257-274.doi: 10.3760/cma.j.cn371439-20210222-00052
Received:2021-02-22
Revised:2021-03-25
Online:2021-05-08
Published:2021-06-09
| [1] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
doi: 10.3322/caac.21338 |
| [2] |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 can-cers from 322 population-based registries in 71 countries[J]. Lancet, 2018,391(10125):1023-1075. DOI: 10.1016/S0140-6736(17)33326-3.
doi: S0140-6736(17)33326-3 pmid: 29395269 |
| [3] | 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019,41(1):19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005. |
| [4] | 中国肺癌防治联盟, 中华医学会呼吸病学分会肺癌学组, 中国医师协会呼吸医师分会肺癌工作委员会. 肺癌筛查与管理中国专家共识[J]. 国际呼吸杂志, 2019,39(21):1604-1615. DOI: 10.3760/cma.j.issn.1673-436X.2019.21.002. |
| [5] | 周清华, 范亚光, 王颖, 等. 中国肺癌低剂量螺旋CT筛查指南(2018年版)[J]. 中国肺癌杂志, 2018,21(2):67-75. DOI: 10.3779/j.issn.1009-3419.2018.02.01. |
| [6] |
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner society 2017[J]. Radiology, 284(1):228-243. DOI: 10.1148/radiol.2017161659.
doi: 10.1148/radiol.2017161659 |
| [7] |
Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification[J]. Chest, 2017,151(1):193-203. DOI: 10.1016/j.chest.2016.10.010.
doi: S0012-3692(16)60780-8 pmid: 27780786 |
| [8] |
Travis WD, Brambilla E, Burke AP, et al. Introduction to the 2015 World Health Organization classification of tumors of the lung, pleura, thymus, and heart[J]. J Thorac Oncol, 2015,10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663.
doi: 10.1097/JTO.0000000000000663 |
| [9] | 中华医学会病理学分会胸部疾病学组. 早期(非黏液型附壁生长方式)肺腺癌冷冻切片病理诊断专家共识[J]. 中华病理学杂志, 2019,48(1):3-10. DOI: 10.3760/cma.j.issn.0529-5807.2019.01.002. |
| [10] | 肺神经内分泌肿瘤病理诊断共识专家组. 肺神经内分泌肿瘤病理诊断共识[J]. 中华病理学杂志, 2017,46(1):9-13. DOI: 10.3760/cma.j.issn.0529-5807.2017.01.003. |
| [11] | 刘标, 周晓军. 非小细胞肺癌免疫组化标志物专家共识(2014)[J]. 临床与实验病理学杂志, 2015,31(5):481-487. DOI: 10.13315/j.cnki.cjcep.2015.05.001. |
| [12] | 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组. 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J] 中华病理学杂志, 2016,45(4):217-220. DOI: 10.3760/cma.j.issn.0529-5807.2016.04.001. |
| [13] | 中国非小细胞肺癌ALK检测模式真实世界多中心研究专家组, 中华医学会病理学分会分子病理学组. 中国非小细胞肺癌ALK检测临床实践专家共识[J]. 中华病理学杂志, 2019,48(12):913-920. DOI: 10.3760/cma.j.issn.0529-5807.2019.12.001. |
| [14] | 中国抗癌协会病理专业委员会肺癌学组. ROS1阳性非小细胞肺癌诊断病理专家共识[J]. 中华病理学杂志, 2018,47(4):248-251. DOI: 10.3760/cma.j.issn.0529-5807.2018.04.004. |
| [15] | 中国抗癌协会肿瘤病理专业委员会, 中国临床肿瘤学会肿瘤病理专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会. 非小细胞肺癌专家委员会中国非小细胞肺癌PD-L1表达检测临床病理专家共识[J]. 中华肿瘤杂志, 2020,42(7):513-521. DOI: 10.3760/cma.j.cn112152-20200313-00202. |
| [16] |
Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiothe-rapy versus lobectomy for operable stage Ⅰ non-small-cell lung can-cer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015,16(6):630-637. DOI: 10.1016/S1470-2045(15)70168-3.
doi: 10.1016/S1470-2045(15)70168-3 |
| [17] |
Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[J]. N Engl J Med, 2004,350(4):351-360. DOI: 10.1056/NEJMoa031644.
doi: 10.1056/NEJMoa031644 |
| [18] |
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC[J]. N Engl J Med, 2018,379(24):2342-2350. DOI: 10.1056/NEJMoa1809697.
doi: 10.1056/NEJMoa1809697 |
| [19] |
Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010,28(13):2181-2190. DOI: 10.1200/JCO.2009.26.2543.
doi: 10.1200/JCO.2009.26.2543 |
| [20] |
Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage Ⅲ non-small cell lung cancer: rando-mized phase Ⅲ trial RTOG 9410[J]. J Natl Cancer Inst, 2011,103(19):1452-1460. DOI: 10.1093/jnci/djr325.
doi: 10.1093/jnci/djr325 |
| [21] |
Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)[J]. J Clin Oncol, 2007,25(3):313-318. DOI: 10.1200/JCO.2006.08.2826.
doi: 10.1200/JCO.2006.08.2826 |
| [22] |
Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017,376(7):629-640. DOI: 10.1056/NEJMoa1612674.
doi: 10.1056/NEJMoa1612674 |
| [23] |
Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017,377(9):829-838. DOI: 10.1056/NEJMoa1704795.
doi: 10.1056/NEJMoa1704795 |
| [24] |
Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014,370(13):1189-1197. DOI: 10.1056/NEJMoa1311107.
doi: 10.1056/NEJMoa1311107 |
| [25] |
Wu YL, Yang JC, Kim DW, et al. Phase Ⅱ study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018,36(14):1405-1411. DOI: 10.1200/JCO.2017.75.5587.
doi: 10.1200/JCO.2017.75.5587 |
| [26] |
Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019,393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7.
doi: 10.1016/S0140-6736(18)32409-7 |
| [27] |
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018,378(22):2078-2092. DOI: 10.1056/NEJMoa1801005.
doi: 10.1056/NEJMoa1801005 |
| [28] |
Verma V, Simone CB 2nd, Allen PK, et al. Outcomes of stereotactic body radiotherapy for T1-T2N0 small cell carcinoma according to addition of chemotherapy and prophylactic cranial irradiation: a multicenter analysis[J]. Clin Lung Cancer, 2017, 18(6): 675-681.e1. DOI: 10.1016/j.cllc.2017.03.009.
doi: 10.1016/j.cllc.2017.03.009 |
| [29] |
Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial[J]. Lancet Oncol, 2009,10(5):467-474. DOI: 10.1016/S1470-2045(09)70101-9.
doi: 10.1016/S1470-2045(09)70101-9 |
| [30] |
Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002,346(2):85-91. DOI: 10.1056/NEJMoa003034.
doi: 10.1056/NEJMoa003034 |
| [31] |
Horn L, Mansfield A, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018,379(23):2220-2229. DOI: 10.1056/NEJMoa1809064.
doi: 10.1056/NEJMoa1809064 |
| [32] |
Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019,394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6.
doi: S0140-6736(19)32222-6 pmid: 31590988 |
| [33] | 王俊. 胸腔镜外科学[M]. 北京: 人民卫生出版社, 2017. |
| [34] | 陈亮, 朱全. 全胸腔镜解剖性肺段切除手术图谱[M]. 南京: 东南大学出版社, 2015. |
| [35] |
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Lung Cancer Study Group[J]. Ann Thorac Surg, 1995, 60(3): 615-622; discussion 622-623. DOI: 10.1016/0003-4975(95)00537-u.
pmid: 7677489 |
| [36] |
Zhang Y, Sun Y, Wang R, et al. Meta-analysis of lobectomy, segmentectomy, and wedge resection for stage Ⅰ non-small cell lung cancer[J]. J Surg Oncol, 2015,111(3):334-340. DOI: 10.1002/jso.23800.
doi: 10.1002/jso.23800 pmid: 25322915 |
| [37] | 庄心良, 曾因明, 陈伯銮. 现代麻醉学[M]. 北京: 人民卫生出版社, 2003. |
| [38] | 孙玉鹗. 胸外科手术学[M]. 北京: 人民军医出版社, 2004. |
| [39] |
Veronesi G, Galetta D, Maisonneuve P, et al. Four-arm robotic lobectomy for the treatment of early-stage lung cancer[J]. J Thorac Cardiovasc Surg, 2010,140(1):19-25. DOI: 10.1016/j.jtcvs.2009.10.025.
doi: 10.1016/j.jtcvs.2009.10.025 |
| [40] |
Liu L, Mei J, Pu Q, et al. Thoracoscopic bronchovascular double sleeve lobectomy for non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2014,46(3):493-495. DOI: 10.1093/ejcts/ezu103.
doi: 10.1093/ejcts/ezu103 |
| [41] | 姜格宁, 陈昶, 朱余明, 等. 上海市肺科医院磨玻璃结节早期肺腺癌的诊疗共识(第一版)[J]. 中国肺癌杂志, 2018,21(3):147-159. DOI: 10.3779/j.issn.1009-3419.2018.03.05. |
| [42] | 周晓红, 唐力, 齐亚灵. 放射性肺炎的预防及治疗研究进展[J]. 医学美学美容, 2014(5):680-682. |
| [43] | 张春伟, 金世柱, 李全晓, 等. 放射性食管炎的临床研究现状[J]. 现代生物医学进展, 2017,17(33):6589-6592. DOI: 10.13241/j.cnki.pmb.2017.33.043. |
| [44] |
Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage Ⅲ non-small-cell lung cancer: a phase Ⅲ randomised controlled trial[J]. Lancet, 2009,374(9687):379-386. DOI: 10.1016/S0140-6736(09)60737-6.
doi: 10.1016/S0140-6736(09)60737-6 pmid: 19632716 |
| [45] |
Brock MV, Hooker CM, Syphard JE, et al. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come[J]. J Thorac Cardiovasc Surg, 2005,129(1):64-72. DOI: 10.1016/j.jtcvs.2004.08.022.
doi: 10.1016/j.jtcvs.2004.08.022 |
| [46] |
Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase Ⅱ trial of postope-rative adjuvant cisplatin and etoposide in patients with completely resected stage Ⅰ-Ⅲa small cell lung cancer: the Japan Clinical Onco-logy Lung Cancer Study Group Trial (JCOG9101)[J]. J Thorac Cardiovasc Surg, 2005,129(5):977-983. DOI: 10.1016/j.jtcvs.2004.05.030.
doi: 10.1016/j.jtcvs.2004.05.030 |
| [47] |
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial[J]. Lancet Oncol, 2006,7(9):719-727. DOI: 10.1016/S1470-2045(06)70804-X.
doi: 10.1016/S1470-2045(06)70804-X |
| [48] |
Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013,31(23):2895-2902. DOI: 10.1200/JCO.2012.47.1102.
doi: 10.1200/JCO.2012.47.1102 |
| [49] |
Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase Ⅲ study addressing the case for cisplatin[J]. Ann Oncol, 2005,16(4):602-610. DOI: 10.1093/annonc/mdi126.
pmid: 15741225 |
| [50] |
Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease[J]. Ann Oncol, 2014,25(8):1475-1484. DOI: 10.1093/annonc/mdu123.
doi: 10.1093/annonc/mdu123 |
| [51] |
Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017,18(11):1454-1466. DOI: 10.1016/S1470-2045(17)30608-3.
doi: 10.1016/S1470-2045(17)30608-3 |
| [52] |
Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020,31(8):1056-1064. DOI: 10.1016/j.annonc.2020.04.478.
doi: 10.1016/j.annonc.2020.04.478 |
| [53] | Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater[J]. J Clin Oncol, 2019,37(7):537-546. DOI: 10.1200/JCO.18.00149. |
| [54] |
Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage ⅠB-ⅢA non-small-cell lung can-cer (RADIANT): a randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2015,33(34):4007-4014. DOI: 10.1200/JCO.2015.61.8918.
doi: 10.1200/JCO.2015.61.8918 |
| [55] |
Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019,20(5):625-635. DOI: 10.1016/S1470-2045(19)30035-X.
doi: 10.1016/S1470-2045(19)30035-X |
| [56] |
Spigel DR, Hainsworth JD, Joseph MJ, et al. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage ⅢB/Ⅳ non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2[J]. Cancer, 2018,124(9):1982-1991. DOI: 10.1002/cncr.30986.
doi: 10.1002/cncr.30986 pmid: 29451696 |
| [57] | Dziadziuszko R, Krebs MG, De Braud F, et al. Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung cancer[J]. J Clin Oncol, 2021: JCO2003025. DOI: 10.1200/JCO.20.03025. |
| [58] |
Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials[J]. Lancet Oncol, 2020,21(2):261-270. DOI: 10.1016/S1470-2045(19)30690-4.
doi: 10.1016/S1470-2045(19)30690-4 |
| [59] |
West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019,20(7):924-937. DOI: 10.1016/S1470-2045(19)30167-6.
doi: 10.1016/S1470-2045(19)30167-6 |
| [60] |
Zhao S, Li X, Zhao C, et al. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M[J]. Lung Cancer, 2019,128:33-39. DOI: 10.1016/j.lungcan.2018.12.010.
doi: S0169-5002(18)30696-2 pmid: 30642450 |
| [61] |
Cheng Y, Fan Y, Liu X, et al. Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancer[J]. Oncol Lett, 2019,17(5):4701-4709. DOI: 10.3892/ol.2019.10125.
doi: 10.3892/ol.2019.10125 pmid: 30988825 |
| [62] |
Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies[J]. J Thorac Oncol, 2020,15(4):618-627. DOI: 10.1016/j.jtho.2019.12.109.
doi: 10.1016/j.jtho.2019.12.109 |
| [63] |
Jie B, Jiang ZM, Nolan MT, et al. Impact of nutritional support on clinical outcome in patients at nutritional risk: a multicenter, prospective cohort study in Baltimore and Beijing teaching hospitals[J]. Nutrition, 2010,26(11-12):1088-1093. DOI: 10.1016/j.nut.2009.08.027.
doi: 10.1016/j.nut.2009.08.027 |
| [64] |
Zhang H, Wang Y, Jiang ZM, et al. Impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: a prospective cohort study with propensity score mathing[J]. Nutrition, 2017,37:53-59. DOI: 10.1016/j.nut.2016.12.004.
doi: S0899-9007(16)30278-7 pmid: 28359363 |
| [65] | 中国抗癌协会, 中国抗癌协会肿瘤营养与支持专业委员会, 中国抗癌协会癌症康复与姑息治疗专业委员会, 等. 肿瘤营养治疗通则[J]. 肿瘤代谢与营养电子杂志, 2016,3(1):28-33. |
| [66] | 中华人民共和国卫生部. 癌症疼痛诊疗规范(2011年版)[J]. 中华危重症医学杂志: 电子版, 2012,17(1):153-158. |
| [67] |
Gadgeel S, Rodríguez-Abreu D, Speranza G, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2020,38(14):1505-1517. DOI: 10.1200/JCO.19.03136.
doi: 10.1200/JCO.19.03136 |
| [68] |
Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: Diagnosis and management of lung can-cer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2013,143(5 Suppl):e211S-e250S. DOI: 10.1378/chest.12-2355.
doi: 10.1378/chest.12-2355 |
| [69] | 王洪武. 现代介入肺脏医学概况[J]. 国际呼吸杂志, 2012,32(4):269-274. DOI: 10.3760/cma.j.issn.1673-436X.2012.004.008. |
| [70] | 北京健康促进会呼吸及肿瘤介入诊疗联盟. 恶性中心气道狭窄经支气管镜介入诊疗专家共识[J]. 中华肺部疾病杂志(电子版), 2017,10(6):647-654. DOI: 10.3877/cma.j.issn.1674-6902.2017.06.004. |
| [71] |
Mudambi L, Miller R, Eapen GA. Malignant central airway obstruction[J]. J Thorac Dis, 2017,9(Suppl 10):S1087-S1110. DOI: 10.21037/jtd.2017.07.27.
doi: 10.21037/jtd |
| [72] | 中华医学会呼吸病学分会. 良性中心气道狭窄经支气管镜介入诊治专家共识[J]. 中华结核和呼吸杂志, 2017,40(6):408-418. DOI: 10.3760/cma.j.issn.1001-0939.2017.06.004. |
| [73] | Zhang J, Wang T, Wang J, et al. Effect of three interventional bronchoscopic methods on tracheal stenosis and the formation of granulation tissues in dogs[J]. Chin Med J (Engl), 2010,123(5):621-627. |
| [74] | 金发光, 刘伟, 殷凯生. 复杂中心气道狭窄的诊断及综合介入治疗现状[J]. 生物医学工程与临床, 2010,14(2):176-179. DOI: 10.3969/j.issn.1009-7090.2010.02.023. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
